Neuropharmacological Profile of an Atypical Antipsychotic, NRA0562

Clinical profile of an atypical antipsychotic: risperidone.

Stimulated by Dawkins and colleagues' (1999) and Remington and Kapur's (2000) calls to develop clinical profiles of the new atypical antipsychotic drugs and by Mattes's critiques (1997, 1998), we performed two sets of analyses for risperidone. First, we reanalyzed data from the North American risperidone trial: risperidone was superior to haloperidol to an equal degree in patients with and with...

What makes an antipsychotic atypical?

Physicochemical properties analysis and dopamine D2 receptor (D2R) docking of zotepine as an atypical antipsychotic antagonist

The main purpose of the present investigation is the study of therapeutically effect of Zotepine in schizophrenia disease treatment. In first step, the molecular structure of the said compound is optimized using density functional theory (DFT) technique by B3LYP functional method at 6-311++G(d,p) level of theory. Then the electronic properties of the title molecule are calculated using frontier...

Introduction: What makes an antipsychotic atypical?

T spectives on this issue tend to define this term differently. To a pharmacologist, it can mean “serotonin-2A (5-HT2A)–dopamine-2 (D2) antagonist” or “multiple simultaneous neurotransmitter binding activities.” To a prescriber, it can mean “low extrapyramidal symptoms” or “reduction of negative symptoms.” To a marketeer, it may mean “new and different.” To a formulary committee with a short-te...

Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat

Objective(s): Olanzapine, an atypical antipsychotic, causes weight gain and metabolic disorders in humans. Safranal, one of the active components of Crocus sativus (saffron), has been shown to have anti-obesity, lipid and blood pressure lowering and anti-diabetes effects. In this investigation, the effect of safranal on metabolic disorders induced by olanzapine was stu...